ViruSure launches first GMP-validated viral safety test using Nanopore Sequencing
ViruSure, in collaboration with Oxford Nanopore Technologies, has introduced the first GMP-validated viral safety test based on nanopore sequencing. Designed for use in biopharmaceutical quality control, this innovative approach enables comprehensive detection of viral contaminants within a single assay.
By replacing multiple traditional testing methods with one sequencing-based solution, the test offers faster turnaround times, broader detection capabilities, and improved efficiency in manufacturing processes. Building on prior GLP validation, this milestone demonstrates the readiness of nanopore sequencing for routine application in regulated environments.
This advancement represents an important step toward more streamlined, reliable, and cost-effective viral safety testing, supporting the continued safety and resilience of biopharmaceutical production.
